COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases.

Clinical decision support aimed at reducing overuse of care in seniors does not yield durable changes in terms of PSA screening in older men, but is durable for reducing urinary overtesting.

The following is a summary of “Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic ...

The following is a summary of “Novel protein C variant p.C101F results in early intracellular degradation that drives type I ...

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...

IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma ...

IPA's strategy melds AI-driven analytics with specialised wet-lab methodologies to design and optimise antibodies.

More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.

The health fair will be held at the Annie Jeffrey Memorial County Health Center in Osceola. This year’s event will be held ...

PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus ...

ImmunoPrecise Antibodies Ltd., an AI-powered antibody company, has partnered with RIBOPRO, a technology provider specializing ...